Guangzhou Wondfo Biotech Co.,Ltd (SHE:300482)
China · Delayed Price · Currency is CNY 15.49
-0.36 (-2.27%)
Nov 13, 2026, 3:04 PM CST
SHE:300482 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 7,196 | 9,174 | 10,709 | 13,338 | 14,088 | 17,522 | |
Market Cap Growth | -30.44% | -14.33% | -19.71% | -5.32% | -19.60% | -42.68% |
Enterprise Value | 5,795 | 8,219 | 9,278 | 12,063 | 13,309 | 16,889 |
Last Close Price | 15.49 | 19.51 | 21.72 | 28.83 | 29.95 | 36.73 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 19.07 | 27.35 | 11.77 | 27.62 |
Forward PE | 22.86 | 18.44 | 14.64 | 21.86 | 12.49 | 19.74 |
PS Ratio | 3.66 | 4.40 | 3.49 | 4.82 | 2.48 | 5.21 |
PB Ratio | 1.33 | 1.68 | 1.90 | 2.89 | 3.11 | 5.00 |
P/TBV Ratio | 1.42 | 1.81 | 2.05 | 3.17 | 3.50 | 5.65 |
P/FCF Ratio | 10.14 | 57.89 | 246.19 | - | 12.82 | 84.06 |
P/OCF Ratio | 7.87 | 19.81 | 29.61 | 40.58 | 8.38 | 26.35 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.95 | 3.94 | 3.03 | 4.36 | 2.34 | 5.03 |
EV/EBITDA Ratio | 35.36 | 84.32 | 11.05 | 17.01 | 8.48 | 20.66 |
EV/EBIT Ratio | - | - | 15.72 | 26.41 | 10.05 | 26.61 |
EV/FCF Ratio | 8.17 | 51.86 | 213.29 | - | 12.11 | 81.03 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.11 | 0.11 | 0.13 | 0.17 | 0.17 |
Debt / EBITDA Ratio | 0.06 | 5.84 | 0.70 | 0.82 | 0.48 | 0.69 |
Debt / FCF Ratio | 0.01 | 3.80 | 13.92 | - | 0.70 | 2.79 |
Net Debt / Equity Ratio | -0.27 | -0.27 | -0.28 | -0.34 | -0.34 | -0.28 |
Net Debt / EBITDA Ratio | -9.24 | -15.38 | -1.90 | -2.23 | -0.98 | -1.21 |
Net Debt / FCF Ratio | -2.06 | -9.46 | -36.60 | 15.20 | -1.39 | -4.74 |
Asset Turnover | 0.31 | 0.30 | 0.47 | 0.46 | 1.02 | 0.73 |
Inventory Turnover | 2.48 | 2.84 | 3.12 | 2.77 | 6.99 | 3.66 |
Quick Ratio | 4.57 | 2.83 | 4.11 | 5.86 | 2.55 | 2.70 |
Current Ratio | 7.34 | 3.18 | 4.61 | 6.68 | 2.94 | 3.27 |
Return on Equity (ROE) | -1.05% | -1.25% | 11.01% | 10.65% | 29.60% | 19.47% |
Return on Assets (ROA) | -0.47% | -1.15% | 5.71% | 4.73% | 14.84% | 8.66% |
Return on Invested Capital (ROIC) | -1.26% | -3.16% | 14.95% | 13.63% | 41.83% | 25.59% |
Return on Capital Employed (ROCE) | -0.90% | -2.30% | 9.30% | 8.60% | 25.70% | 15.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.86% | -0.69% | 5.24% | 3.66% | 8.50% | 3.62% |
FCF Yield | 9.86% | 1.73% | 0.41% | -0.78% | 7.80% | 1.19% |
Dividend Yield | 1.42% | 1.21% | 1.79% | 1.32% | 1.57% | 0.76% |
Payout Ratio | - | - | 34.93% | 46.75% | 11.73% | 27.38% |
Buyback Yield / Dilution | 0.37% | -4.45% | -4.71% | -0.36% | 0.44% | -0.74% |
Total Shareholder Return | 1.79% | -3.23% | -2.92% | 0.97% | 2.00% | 0.02% |